+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.

Age: 18Years +All GendersPhase 3
318 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of AZD6234 in adults who have obesity or are overweight with at least one weight-related health condition but do not have type 2 diabetes. This Phase III study is randomized, double-blind, and conducted across multiple centers worldwide. Participants will be assigned to receive either AZD6234 or a placebo to compare changes in body weight over 68 weeks of treatment. The study treatments involve subcutaneous injections once a week. Participants will receive one of two doses of AZD6234 or a matching placebo. The trial aims to assess how these treatments affect body weight, waist circumference, triglycerides, blood pressure, and fat mass, including measurements by DXA scans in a subset of participants. The treatment period lasts 68 weeks. During the study, participants will have regular visits for assessments including body weight, waist circumference, blood pressure, and blood tests. Some will have DXA scans to measure fat mass. Researchers will monitor safety and track the percentage change in body weight from the start of treatment. The total participation duration includes 68 weeks of treatment with monitoring at specified intervals.

Age: 18Years +All GendersPhase 3
220 locations
E

Actively Recruiting

The trial investigates how well AZD6234 works and its safety in adults who have Type 2 Diabetes Mellitus along with obesity or excess weight. This Phase III, global, randomized, double-blind study compares AZD6234 to a placebo to measure changes in body weight over 68 weeks of treatment. The study aims to better understand weight loss effects and related health changes in this population. Participants will be randomly assigned to one of three groups two different doses of AZD6234 or a placebo. The treatments are given by weekly subcutaneous injections. The study will last 68 weeks, during which participants receive their assigned injections and are monitored regularly for effectiveness and safety. Throughout the study, participants will attend multiple visits for evaluations, including body weight, waist circumference, blood pressure, and lab tests such as haemoglobin A1C and triglycerides. Some may undergo DXA scans to measure fat mass. Researchers will track changes from baseline to assess weight loss and metabolic effects. Safety and tolerability will also be monitored over the treatment period, which lasts about 68 weeks.

Age: 18Years +All GendersPhase 3
230 locations
R

Actively Recruiting

Researchers are evaluating the effects of biweekly XEMBIFY combined with Standard Medical Treatment SMT over one year in adults with hypogammaglobulinemia HGG who have B-cell Chronic Lymphocytic Leukemia CLL, Multiple Myeloma MM, or Non-Hodgkin Lymphoma NHL. The study aims to determine if this combination reduces the yearly rate of major bacterial infections compared to a placebo plus SMT. This Phase 3 trial is randomized, double-blinded, and placebo-controlled to ensure reliable results. Participants will receive either XEMBIFY or a placebo via subcutaneous infusion. The treatment starts with a loading dose of 150 mgkgday given daily for five days in the first week, followed by biweekly infusions of 300 mgkg from Week 3 through Week 51. Along with the study drug or placebo, all participants will continue to receive their usual standard medical treatments and supportive care needed during the trial. During the study, participants will be regularly monitored to assess the rate and timing of major bacterial infections and other infection-related outcomes. Researchers will track hospitalizations, antibiotic use, and overall infection rates up to Week 51. Safety and pharmacokinetics of the treatment will also be evaluated throughout. The total participation period lasts about one year, during which participants will have scheduled visits for treatment administration and assessments.

Age: 18Years +All GendersPhase 3
62 locations
T

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.

Age: 18Years +All GendersPhase 3
594 locations
E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of DPX-Survivac combined with pembrolizumab, with and without low-dose cyclophosphamide CPA, in adults with relapsed or refractory diffuse large B-cell lymphoma DLBCL. This Phase 2b, randomized, open-label study aims to better understand how these treatments work in this group of patients who have had previous therapies. The study is sponsored by ImmunoVaccine Technologies, Inc. IMV Inc.. Participants will be randomly assigned to one of two groups one group receives DPX-Survivac, pembrolizumab, and intermittent low-dose CPA, while the other group receives DPX-Survivac and pembrolizumab without CPA. DPX-Survivac is given as two 0.5 mL doses three weeks apart on days 7 and 28, followed by up to twelve 0.1 mL doses every eight weeks. Pembrolizumab is administered intravenously at 200 mg on day 7 and then every three weeks. In the CPA group, subjects take 50 mg of oral CPA twice daily for 7 days followed by 7 days off, repeating this cycle throughout the treatment period. During the study, participants will undergo assessments to monitor tumor response and safety for about 24 months, with some measures extending up to 48 months. Researchers will evaluate objective response rates, adverse events, duration and time to response, progression-free survival, and disease control rates. Patient-reported outcomes will be collected using specific questionnaires. The study involves regular visits for treatment administration, tumor biopsies, and laboratory tests to track the participants health and treatment effects over time.

Age: 18Years +All GendersPhase 2
50 locations
S

Actively Recruiting

Researchers are evaluating the effects of intravenous ferric carboxymaltose FCM compared with a placebo on death risk, heart failure events, NT-proBNP levels, and quality of life in patients who recently had an acute myocardial infarction AMI and have iron deficiency. This phase 4, multicenter, randomized, double-blind, placebo-controlled clinical trial aims to assess these outcomes over a follow-up period ranging from 8 to 36 months. Participants are randomly assigned to receive either an intravenous 15-minute infusion of 1000 mg FCM diluted in saline or a placebo infusion of saline alone. The first dose is given on the day of randomization, with follow-up visits at 4, 8, 12, 18, 24, and 30 months to reassess participants and possibly repeat treatment if safety criteria are met. During the study, participants undergo evaluations including monitoring of death rates, heart failure events such as unplanned hospitalizations or emergency visits, changes in NT-proBNP concentration, and quality of life measured by the EQ-5D questionnaire. Safety and treatment effects are tracked throughout the follow-up period, which can last up to 36 months from the start of participation.

Age: 18Years - 90YearsAll GendersPhase 4
43 locations
S

Actively Recruiting

Researchers are analyzing outcomes from patients who underwent percutaneous coronary intervention PCI for coronary artery disease involving bifurcation lesions. The study compares two different two-stent techniques the Culotte technique and the Double Kiss DK Culotte technique. This retrospective study uses data collected from two high-volume cardiac centers in the Lower Silesia Region between April 2012 and January 2024. The choice of which stent technique to use was made by the treating physician based on clinical and angiographic factors, with no restrictions on lesion characteristics. Patients included had bifurcation lesions treated with either the classical Culotte technique or the DK-Culotte technique, which involves an additional balloon dilation step after side branch stenting. The study groups consist of patients treated with one of these two stenting methods. The PCI was performed following standard clinical indications, with all patients informed about treatment options and risks before consenting. Patients who had previous stenting of the same bifurcation lesion before the procedure were excluded. Participants outcomes are monitored retrospectively over a 5-year period following their initial hospital stay. The primary outcome measured is target lesion failure, with evaluations every 6 months after hospital discharge. Secondary outcomes include major adverse cardiac events MACE. This long-term follow-up allows researchers to assess the safety and effectiveness of the two-stent techniques over time using clinical records and data analysis.

Age: 18Years +All Genders
2 locations
S

Actively Recruiting

This research focuses on patients with moderately to severely calcified lesions in their coronary arteries who undergo percutaneous coronary intervention PCI. The study aims to collect data on the safety and effectiveness of PCI when supported by the Orbital Atherectomy Device. Patients are selected based on clinical indication according to current European Society of Cardiology guidelines and the presence of significant calcification assessed by angiography or intravascular imaging techniques like IVUS or OCT. The study involves patients treated at two cardiac centers in Poland where the decision to use the Orbital Atherectomy Device during PCI is made by the operator based on lesion characteristics. Moderate calcification is defined as involving 30% to 50% of the lesion diameter, while severe calcification involves more than 50%. The procedure details, including additional lesion preparation, stent implantation, medication, and imaging use, are determined by the treating physician. All patients give informed consent after being advised about treatment options and risks. Participants will be monitored at discharge up to 10 days to assess clinical success and any treatment-emergent adverse events. Long-term follow-up includes evaluation of major adverse cardiac and cerebrovascular events for up to five years after hospitalization, with assessments every six months. The study collects comprehensive data on treatment outcomes and safety during and after the procedure, supporting ongoing patient care and research.

Age: 18Years +All Genders
2 locations

1-10 of 12

1